Research news and updates

The AAT funds new research into COVID-19 vaccination responses in patients with aplastic anaemia and PNH

The new study will shed light on the question of how effective the Covid-19 vaccines are in aplastic anaemia patients. Read more

Do people with aplastic anaemia and/or PNH respond to the Covid-19 vaccines? Our research indicates, YES!

On December 6th, The Aplastic Anaemia Trust community received this update from the research team in Leeds about their study into the Covid-19 vaccine and people with aplastic anaemia and PNH. Watch the full presentation here! Read more

Update on the production of expanded autologous regulatory T cells to treat patients with refractory aplastic anaemia

Good progress made up until the Covid-19 crisis. Work set to resume once lockdown restrictions have been eased. Read more

Novel somatic mutations in aplastic anaemia patients

Update on a project led by the researchers at King’s College Hospital/King’s College London, funded by the AAT, April 2020 Read more

Update on the establishment of paediatric aplastic anaemia registry and biobank

A project run by researchers at Great Ormond Street Hospital, London, funded by the AAT and its generous supporters Read more

Compelling case for upfront HLA-matched unrelated donor stem cell transplant as a curative treatment fo adult SAA

Funds from Bloodwise, Cancer Research UK and the AAT, enable Professor Judith Marsh and colleagues to make a compelling argument. Read more

Results of an early study of CXCR4-blocking drug BL-8040, combined with immune-suppressive therapy

Encouraging to see new compounds being tested in the treatment of aplastic anaemia, narrated by Dr Laura Jardine, Newcastle University Read more

Study into success rates of half-matched stem cell transplant compared with standard first-line treatment of young patients with severe aplastic anaemia

Update from researchers in China, narrated by Laura Jardine, Newcastle University Read more

Eculizumab used in the treatment of PNH

A final piece of news from the 23rd Annual Congress of the European Haematology Association on the use of Eculizumab in PNH Read more

Phase 1 study on combining BL8040 compound with IST

News from the 23rd Annual Congress of the European Haematology Association on an exciting study taking place at the MD Anderson Cancer Centre in Texas Read more

Eltrombopag use as a single agent

More news from the 23rd Annual Congress of the European Haematology Association (EHA) in Stockholm. Here is the feedback on the use of Eltrombopag as a single agent Read more

T-reg project - Quarter 1, 2020 update

Revolutionary discovery of treatment using T-regulatory cells Read more

Positive reports from extended use of Eltrombopag

Encouraging results from a study into the use of Eltrombopag show that extended use of the drug at a fixed dose could speed and improve patients' response rates Read more

Promising results from Eculizumab trials for patients with PNH

Eculizumab has revolutionised the treatment of PNH, offering freedom from blood transfusion and independence to a large number of patients Read more

Positive outcomes from the international bone marrow registry database in patients aged 50+ with AA

Stem cell transplant is a very feasible option in a good proportion of patients who might be elderly, but are otherwise fit and healthy Read more